AKEBIA THERAPEUTICS, INC. Goodwill, Impaired, Accumulated Impairment Loss
AKEBIA THERAPEUTICS, INC. (AKBA) had Goodwill, Impaired, Accumulated Impairment Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:GoodwillImpairedAccumulatedImpairmentLoss · last filed 2026-08-05
- 2026-06-30: Goodwill, Impaired, Accumulated Impairment Loss $0.00.
- 2026-03-31: Goodwill, Impaired, Accumulated Impairment Loss $0.00.
- 2025-12-31: Goodwill, Impaired, Accumulated Impairment Loss $0.00.
- 2025-09-30: Goodwill, Impaired, Accumulated Impairment Loss $0.00.
| Period end | Goodwill, Impaired, Accumulated Impairment Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-28 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |